Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a 1,5-benzodiazepine with a structure distinct from 1,4-benzodiazepines (e.g., diazepam, lorazepam). It acts as a positive allosteric modulator of the GABA-A receptor. It has a longer half-life than many other benzodiazepines and is primarily metabolized by CYP2C19.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
* Off-label: Management of refractory focal or generalized epilepsy and acute anxiety (rarely first-line).
## Adult Dosing
* **Initial:** 5 mg twice daily (10 mg/day).
* **Titration:** Increase at weekly intervals based on clinical response and tolerability.
* **Maintenance:** Typically 20 mg/day (given as 10 mg twice daily).
* **Maximum:** 40 mg/day (doses >20 mg/day have not been proven to provide additional benefit and significantly increase risk of adverse events).
## Pediatric Dosing (≥ 2 years)
Weight-based dosing is required for patients ≤ 30 kg.
* **Weight ≤ 30 kg:**
* Initial: 5 mg/day.
* Titration: Increase after 1 week to 10 mg/day.
* Maximum: 20 mg/day.
* **Weight > 30 kg:**
* Initial: 5 mg twice daily (10 mg/day).
* Titration: Increase after 1 week to 20 mg/day.
* Maximum: 40 mg/day.
## Dose Adjustments
* **Hepatic Impairment:** Reduce initial dose by 50%. Use with extreme caution in severe impairment; monitor for excessive sedation.
* **Renal Impairment:** No specific adjustment necessary, but use caution as metabolites may accumulate.
* **CYP2C19 Poor Metabolizers:** Utilize lower starting doses and slower titration, as plasma levels of the active metabolite (N-desmethylclobazam) will be significantly elevated.
## Contraindications
* Known hypersensitivity to clobazam.
* History of severe drug-induced skin reactions (e.g., SJS/TEN).
## Adverse Effects
* **Common:** Somnolence, pyrexia, lethargy, drooling, constipation, urinary tract infection, irritability, and ataxia.
* **Serious:** Severe dermatological reactions (Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), respiratory depression, physical dependence/withdrawal symptoms upon cessation, and suicidal ideation.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of severe sedation and respiratory depression when combined with opioids, alcohol, or other sedative-hypnotics.
* **CYP2C19 Inducers/Inhibitors:** Fluconazole, fluvoxamine, and omeprazole (inhibitors) can increase clobazam levels; rifampin (inducer) can decrease levels.
* **Valproate:** May increase concentrations of the active metabolite N-desmethylclobazam.
* **Oral Contraceptives:** May decrease the efficacy of hormonal contraceptives; suggest non-hormonal backup.
## Monitoring
* **Clinical:** Monitor for excessive sedation, irritability, and worsening seizure frequency.
* **Dermatological:** Patients/caregivers must be educated to report any signs of skin rash, blistering, or mucosal lesions immediately.
* **Withdrawal:** Monitor for rebound seizures or withdrawal symptoms if the medication is discontinued (must be tapered slowly).
## Clinical Pearls
* **Suspension:** The oral suspension should be shaken well before use, and the included calibrated measuring device must be used.
* **Switching:** If switching from a different benzodiazepine, overlap the medications during titration to prevent withdrawal.
* **Tolerance:** Long-term efficacy can be limited by the development of tolerance to anticonvulsant effects. If seizures break through, re-evaluate dosage or adjunctive therapy.
***
**Disclaimer:** This information is for educational purposes only. Clinical dosing and management should be tailored to individual patient needs and institutional protocols. Always consult the most current prescribing information (e.g., FDA-approved package insert) and clinical drug databases before prescribing or administering medication.
